Figure 2.

Evaluation of the treatments on the production of Aβ40/42 in HEK293 cell by ELISA. (A) BER (1 μM, 5 μM, 10 μM, and 20 μM) can inhibit the production of Aβ40 for 48 hours of incubation,*P < 0.01 compared with vehicle-treated group, #P < 0.05 compared with BER (1 μM) groups (n = 5). (B) BER (5 μM) can inhibit the production of Aβ40 from 8 to 72 hours of incubation, *P < 0.01 compared with vehicle-treated group, #P > 0.05 compared with BER (8 h) groups (n = 5). (C) U0126 (0.5 μM) can abolish the inhibition of BER (5 μM) on the production of Aβ40, *P < 0.01 compared with vehicle-treated group, #P < 0.05 compared with vehicle-treated group (n = 5). (D) BER (1 μM, 5 μM, 10 μM, and 20 μM) can inhibit the production of Aβ42 for 48 hours of incubation,*P < 0.01 compared with the vehicle-treated group, #P < 0.05 compared with BER (1 μM and 5 μM) groups (n = 5). (E) BER (5 μM) can inhibit the production of Aβ42 from 8 to 72 hours of incubation, *P < 0.01 compared with the vehicle-treated group, #P < 0.05 compared with BER (8- and 24-hour) groups (n = 5). (F) U0126 (0.5 μM) can abolish the inhibition of BER (5 μM) on the production of Aβ42, *P < 0.01 compared with vehicle-treated group, #P < 0.05 compared with vehicle-treated group (n = 5).

Zhu et al. BMC Neuroscience 2011 12:125   doi:10.1186/1471-2202-12-125
Download authors' original image